|
1
|
Heinemann V, von Weikersthal LF, Decker T,
Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller
C, Kahl C, Seipelt G, et al: FOLFIRI plus cetuximab versus FOLFIRI
plus bevacizumab as first-line treatment for patients with
metastatic colorectal cancer (FIRE-3): A randomised, open-label,
phase 3 trial. Lancet Oncol. 15:1065–1075. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lenz HJ, Ou FS, Venook AP, Hochster HS,
Niedzwiecki D, Goldberg RM, Mayer RJ, Bertagnolli MM, Blanke CD,
Zemla T, et al: Impact of consensus molecular subtype on survival
in patients with metastatic colorectal cancer: Results From
CALGB/SWOG 80405 (Alliance). J Clin Oncol. 37:1876–1885. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Schwartzberg LS, Rivera F, Karthaus M,
Fasola G, Canon JL, Hecht JR, Yu H, Oliner KS and Go WY: PEAK: A
randomized, multicenter phase II study of panitumumab plus modified
fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab
plus mFOLFOX6 in patients with previously untreated, unresectable,
wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol.
32:2240–2247. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Saltz LB, Clarke S, Díaz-Rubio E,
Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS,
Rivera F, et al: Bevacizumab in combination with oxaliplatin-based
chemotherapy as first-line therapy in metastatic colorectal cancer:
A randomized phase III study. J Clin Oncol. 26:2013–2019. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sobrero A, Lenz HJ, Eng C, Scheithauer W,
Middleton G, Chen W, Esser R, Nippgen J and Burris H: Extended RAS
analysis of the phase III EPIC trial: Irinotecan + Cetuximab versus
irinotecan as second-line treatment for patients with metastatic
colorectal cancer. Oncologist. 26:e261–e269. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bennouna J, Sastre J, Arnold D, Österlund
P, Greil R, Van Cutsem E, von Moos R, Viéitez JM, Bouché O, Borg C,
et al: Continuation of bevacizumab after first progression in
metastatic colorectal cancer (ML18147): A randomised phase 3 trial.
Lancet Oncol. 14:29–37. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tabernero J, Yoshino T, Cohn AL,
Obermannova R, Bodoky G, Garcia-Carbonero R, Ciuleanu TE, Portnoy
DC, Van Cutsem E, Grothey A, et al: Ramucirumab versus placebo in
combination with second-line FOLFIRI in patients with metastatic
colorectal carcinoma that progressed during or after first-line
therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine
(RAISE): A randomised, double-blind, multicentre, phase 3 study.
Lancet Oncol. 16:499–508. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tabernero J, Van Cutsem E, Lakomý R,
Prausová J, Ruff P, van Hazel GA, Moiseyenko VM, Ferry DR,
McKendrick JJ, Soussan-Lazard K, et al: Aflibercept versus placebo
in combination with fluorouracil, leucovorin and irinotecan in the
treatment of previously treated metastatic colorectal cancer:
Prespecified subgroup analyses from the VELOUR trial. Eur J Cancer.
50:320–331. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Neufeld G, Cohen T, Gengrinovitch S and
Poltorak Z: Vascular endothelial growth factor (VEGF) and its
receptors. FASEB J. 13:9–22. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ferrara N: Molecular and biological
properties of vascular endothelial growth factor. J Mol Med (Berl).
77:527–543. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Carmeliet P and Jain RK: Angiogenesis in
cancer and other diseases. Nature. 407:249–257. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Leung DW, Cachianes G, Kuang WJ, Goeddel
DV and Ferrara N: Vascular endothelial growth factor is a secreted
angiogenic mitogen. Science. 246:1306–1309. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Inoue M, Hager JH, Ferrara N, Gerber HP
and Hanahan D: VEGF-A has a critical, nonredundant role in
angiogenic switching and pancreatic beta cell carcinogenesis.
Cancer Cell. 1:193–202. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
de Vries C, Escobedo JA, Ueno H, Houck K,
Ferrara N and Williams LT: The fms-like tyrosine kinase, a receptor
for vascular endothelial growth factor. Science. 255:989–991. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Placencio VR and DeClerck YA: Plasminogen
activator inhibitor-1 in cancer: Rationale and insight for future
therapeutic testing. Cancer Res. 75:2969–2974. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Binder BR and Mihaly J: The plasminogen
activator inhibitor ‘paradox’ in cancer. Immunol Lett. 118:116–124.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nielsen HJ, Christensen IJ, Sørensen S,
Moesgaard F and Brünner N: Preoperative plasma plasminogen
activator inhibitor type-1 and serum C-reactive protein levels in
patients with colorectal cancer. The RANX05 colorectal cancer study
group. Ann Surg Oncol. 7:617–623. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Van Cutsem E, Paccard C, Chiron M and
Tabernero J: Impact of prior bevacizumab treatment on VEGF-A and
PlGF levels and outcome following second-line aflibercept
treatment: Biomarker Post Hoc analysis of the VELOUR trial.
Clin Cancer Res. 26:717–725. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Presta LG, Chen H, O'Connor SJ, Chisholm
V, Meng YG, Krummen L, Winkler M and Ferrara N: Humanization of an
anti-vascular endothelial growth factor monoclonal antibody for the
therapy of solid tumors and other disorders. Cancer Res.
57:4593–4599. 1997.PubMed/NCBI
|
|
20
|
Suzuki T, Shinozaki E, Osumi H, Nakayama
I, Ota Y, Ichimura T, Ogura M, Wakatsuki T, Ooki A, Takahari D, et
al: Second-line FOLFIRI plus ramucirumab with or without prior
bevacizumab for patients with metastatic colorectal cancer. Cancer
Chemother Pharmacol. 84:307–313. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Niki M, Yokoi T, Kurata T and Nomura S:
New prognostic biomarkers and therapeutic effect of bevacizumab for
patients with non-small-cell lung cancer. Lung Cancer (Auckl).
8:91–99. 2017.PubMed/NCBI
|
|
22
|
Liu Y, Starr MD, Brady JC, Rushing C, Pang
H, Adams B, Alvarez D, Theuer CP, Hurwitz HI and Nixon AB:
Modulation of circulating protein biomarkers in cancer patients
receiving bevacizumab and the anti-endoglin antibody, TRC105. Mol
Cancer Ther. 17:2248–2256. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bal O, Ekinci AS, Dogan M, Atay C, Demirci
A, Oksuzoglu B and Kilic S: The prognostic and predictive
significance of plasma type 1 plasminogen activator inhibitor and
endoglin in metastatic colorectal cancer patients treated with
bevacizumab-containing chemotherapy. J Cancer Res Ther. 15:48–53.
2019.PubMed/NCBI
|
|
24
|
Bajou K, Noël A, Gerard RD, Masson V,
Brunner N, Holst-Hansen C, Skobe M, Fusenig NE, Carmeliet P, Collen
D and Foidart JM: Absence of host plasminogen activator inhibitor 1
prevents cancer invasion and vascularization. Nat Med. 4:923–928.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bajou K, Maillard C, Jost M, Lijnen RH,
Gils A, Declerck P, Carmeliet P, Foidart JM and Noel A:
Host-derived plasminogen activator inhibitor-1 (PAI-1)
concentration is critical for in vivo tumoral angiogenesis and
growth. Oncogene. 23:6986–6990. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Takayama Y, Hattori N, Hamada H, Masuda T,
Omori K, Akita S, Iwamoto H, Fujitaka K and Kohno N: Inhibition of
PAI-1 limits tumor angiogenesis regardless of angiogenic stimuli in
malignant pleural mesothelioma. Cancer Res. 76:3285–3294. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Naitoh H, Eguchi Y, Ueyama H, Kodama M and
Hattori T: Localization of urokinase-type plasminogen activator,
plasminogen activator inhibitor-1, 2 and plasminogen in colon
cancer. Jpn J Cancer Res. 86:48–56. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tabernero J, Hozak RR, Yoshino T, Cohn AL,
Obermannova R, Bodoky G, Garcia-Carbonero R, Ciuleanu TE, Portnoy
DC, Prausová J, et al: Analysis of angiogenesis biomarkers for
ramucirumab efficacy in patients with metastatic colorectal cancer
from RAISE, a global, randomized, double-blind, phase III study.
Ann Oncol. 29:602–609. 2018. View Article : Google Scholar : PubMed/NCBI
|
